EA201491324A1 - Средства и методы лечения или диагностики раковых заболеваний с мутацией r132h в гене idh1 - Google Patents
Средства и методы лечения или диагностики раковых заболеваний с мутацией r132h в гене idh1Info
- Publication number
- EA201491324A1 EA201491324A1 EA201491324A EA201491324A EA201491324A1 EA 201491324 A1 EA201491324 A1 EA 201491324A1 EA 201491324 A EA201491324 A EA 201491324A EA 201491324 A EA201491324 A EA 201491324A EA 201491324 A1 EA201491324 A1 EA 201491324A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- peptide
- cancer
- amino acid
- amino acids
- mutation
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 6
- 201000011510 cancer Diseases 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 4
- 230000035772 mutation Effects 0.000 title abstract 3
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 title 1
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 7
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 4
- 230000027455 binding Effects 0.000 abstract 2
- 210000000987 immune system Anatomy 0.000 abstract 2
- 238000006467 substitution reaction Methods 0.000 abstract 2
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 abstract 1
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 229940126534 drug product Drugs 0.000 abstract 1
- 101150046722 idh1 gene Proteins 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000009870 specific binding Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01042—Isocitrate dehydrogenase (NADP+) (1.1.1.42)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/904—Oxidoreductases (1.) acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
Abstract
Изобретение относится к области терапевтических и диагностических средств для применения в онкологии. В частности, оно относится к пептиду, включающему по меньшей мере 8 аминокислот в длину, которые присутствуют в виде смежных аминокислот в аминокислотной последовательности человеческой изоцитратдегидрогеназы типа 1 (IDH1), где упомянутый пептид имеет по меньшей мере одну аминокислотную замену R на Н в положении, соответствующем позиции 132, для применения при профилактике и/или лечении раковых заболеваний. Дополнительно предлагается лекарственное средство, включающее упомянутый пептид. Кроме того, изобретение относится к методу диагностики рака, характеризующемуся наличием мутации в геноме, по меньшей мере, некоторых раковых клеток, которая приводит к экспрессии мутантного гена IDH1, имеющего мутацию R132H. Метод включает этапы контактирования образца крови субъекта, который, как предполагается, страдает от такого ракового заболевания, с пептидом, включающим по меньшей мере 10 аминокислот в длину, которые присутствуют в виде смежных аминокислот в аминокислотной последовательности IDH1, где упомянутый пептид имеет по меньшей мере одну аминокислотную замену R на Н в положении, соответствующем позиции 132, в течение промежутка времени и в условиях, позволяющих произойти специфическому связыванию компонента иммунной системы с пептидом, и определения, произошло или нет связывание упомянутого компонента иммунной системы с пептидом, причем рак диагностируют, если подтверждается наличие связывания. В изобретении предлагаются также набор и устройство для проведения упомянутого метода.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12150298 | 2012-01-05 | ||
| PCT/EP2013/050048 WO2013102641A1 (en) | 2012-01-05 | 2013-01-03 | Means and methods for treating or diagnosing idh1 r132h mutant-positive cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201491324A1 true EA201491324A1 (ru) | 2015-03-31 |
Family
ID=47559460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201491324A EA201491324A1 (ru) | 2012-01-05 | 2013-01-03 | Средства и методы лечения или диагностики раковых заболеваний с мутацией r132h в гене idh1 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10161940B2 (ru) |
| EP (1) | EP2800580B1 (ru) |
| JP (1) | JP6316755B2 (ru) |
| KR (1) | KR102055463B1 (ru) |
| CN (1) | CN105142662B (ru) |
| AU (1) | AU2013207191B2 (ru) |
| BR (1) | BR112014016612A2 (ru) |
| CA (1) | CA2859078A1 (ru) |
| EA (1) | EA201491324A1 (ru) |
| ES (1) | ES2642184T3 (ru) |
| HK (1) | HK1203825A1 (ru) |
| MX (1) | MX349494B (ru) |
| SG (1) | SG11201403877PA (ru) |
| WO (1) | WO2013102641A1 (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3749349A4 (en) * | 2018-02-10 | 2021-11-24 | Berkeley Lights, Inc. | MUTANT IDH1 SPECIFIC T CELL RECEPTOR |
| CN112239787B (zh) * | 2019-07-19 | 2024-05-10 | 河南远止生物技术有限公司 | 一种检测人idh1基因突变的引物和探针、试剂盒和装置 |
| WO2021014398A1 (en) * | 2019-07-23 | 2021-01-28 | University Of Rijeka Faculty Of Medicine | Integrated human cytomegalovirus / glioblastoma vaccine |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE481485T1 (de) * | 1998-05-01 | 2010-10-15 | Texas A & M Univ Sys | Cd86 aus katzen |
| GB9810276D0 (en) * | 1998-05-13 | 1998-07-15 | Smithkline Beecham Biolog | Novel compounds |
| DE69938670D1 (de) * | 1998-12-23 | 2008-06-19 | Id Biomedical Corp | Streptococcus antigene |
| WO2010028099A1 (en) * | 2008-09-03 | 2010-03-11 | The Johns Hopkins University | Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma |
| WO2010105243A1 (en) * | 2009-03-13 | 2010-09-16 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| EP2412825B8 (en) * | 2009-03-24 | 2018-01-10 | Riken | Leukemia stem cell markers |
| EP2253716A1 (en) * | 2009-05-15 | 2010-11-24 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Diagnostic methods for the prognosis of a brain tumor |
-
2013
- 2013-01-03 CN CN201380004722.8A patent/CN105142662B/zh not_active Expired - Fee Related
- 2013-01-03 EP EP13700266.3A patent/EP2800580B1/en active Active
- 2013-01-03 WO PCT/EP2013/050048 patent/WO2013102641A1/en active Application Filing
- 2013-01-03 CA CA2859078A patent/CA2859078A1/en not_active Abandoned
- 2013-01-03 SG SG11201403877PA patent/SG11201403877PA/en unknown
- 2013-01-03 EA EA201491324A patent/EA201491324A1/ru unknown
- 2013-01-03 KR KR1020147021779A patent/KR102055463B1/ko active IP Right Grant
- 2013-01-03 US US14/370,224 patent/US10161940B2/en active Active
- 2013-01-03 MX MX2014008306A patent/MX349494B/es active IP Right Grant
- 2013-01-03 AU AU2013207191A patent/AU2013207191B2/en not_active Ceased
- 2013-01-03 JP JP2014550699A patent/JP6316755B2/ja active Active
- 2013-01-03 BR BR112014016612A patent/BR112014016612A2/pt not_active Application Discontinuation
- 2013-01-03 ES ES13700266.3T patent/ES2642184T3/es active Active
-
2015
- 2015-05-07 HK HK15104348.4A patent/HK1203825A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102055463B1 (ko) | 2019-12-12 |
| SG11201403877PA (en) | 2014-09-26 |
| JP2015505246A (ja) | 2015-02-19 |
| HK1203825A1 (en) | 2015-11-06 |
| WO2013102641A1 (en) | 2013-07-11 |
| MX2014008306A (es) | 2015-03-03 |
| CN105142662A (zh) | 2015-12-09 |
| CN105142662B (zh) | 2017-07-07 |
| AU2013207191A1 (en) | 2014-07-03 |
| EP2800580A1 (en) | 2014-11-12 |
| EP2800580B1 (en) | 2017-07-12 |
| AU2013207191B2 (en) | 2017-10-26 |
| KR20140120324A (ko) | 2014-10-13 |
| MX349494B (es) | 2017-08-01 |
| BR112014016612A2 (pt) | 2017-06-27 |
| CA2859078A1 (en) | 2013-07-11 |
| US20150023991A1 (en) | 2015-01-22 |
| US10161940B2 (en) | 2018-12-25 |
| ES2642184T3 (es) | 2017-11-15 |
| JP6316755B2 (ja) | 2018-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019010958A (es) | Metodos de tratamiento de tumores. | |
| WO2017081211A3 (en) | Antigen-binding polypeptides directed against cd38 | |
| EA201891435A1 (ru) | Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47 | |
| ZA201604468B (en) | Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis | |
| EP2987807A3 (en) | Antibodies recognising phospho-tau | |
| MY183989A (en) | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease | |
| MX354662B (es) | Anticuerpos fosfoespecificos que reconocen la tau. | |
| AR092818A1 (es) | Anticuerpo tau humanizado | |
| WO2012174282A3 (en) | Biomarker compositions and methods | |
| WO2013134786A3 (en) | Biomarker compositions and methods | |
| WO2013022995A3 (en) | Biomarker compositions and methods | |
| NO20091736L (no) | IL-17-reseptor A-antigenbindende proteiner | |
| WO2011106541A3 (en) | Diagnostic methods involving loss of heterozygosity | |
| MX2015000686A (es) | Metodo para detectar cancer. | |
| EA201491324A1 (ru) | Средства и методы лечения или диагностики раковых заболеваний с мутацией r132h в гене idh1 | |
| EA201290107A1 (ru) | Способ определения пациента как восприимчивого или не восприимчивого к иммунотерапии | |
| WO2014117680A3 (zh) | 外周血细胞TRPC6mRNA水平用于早期预测/诊断老年性痴呆 | |
| WO2014059196A3 (en) | Diagnosis and treatment of sma and smn deficiency | |
| MX2011008456A (es) | Anticuerpos anti-mst1r y usos de los mismos. | |
| MY148542A (en) | A method for the assessment of cancer in a biological sample obtained from a subject | |
| BR112014023496A2 (pt) | mutantes c-raf que conferem resistência a inibidores de raf | |
| WO2013106766A3 (en) | THERAPEUTIC INDICATIONS OF miR-1291 | |
| MX2016014779A (es) | Prueba de diagnostico y tratamiento/prevencion de la enfermedad de alzheimer. | |
| WO2013113942A3 (en) | Novel fusion genes in lung cancer | |
| WO2014016584A3 (en) | Diagnostic for determining skeletal health |